Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 550

Sort by

Sort Order Select

Journal Articles

Targeting ephrin A3 in the bone marrow niche offers a promising therapeutic strategy to impede hematopoietic stem cell maintenance in MDS patients

Blood (2025) 146 (Supplement 1): 859.

https://doi.org/10.1182/blood-2025-859

Published: 2025

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

Blood (2025) 146 (Supplement 1): 3847.

https://doi.org/10.1182/blood-2025-3847

Published: 2025

Journal Articles

Characteristics and prognostic significance of myelodysplastic syndrome (MDS)-related features in vexas syndrome

Blood (2025) 146 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2025-3165

Published: 2025

Journal Articles

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Blood (2025) 146 (Supplement 1): 2070.

https://doi.org/10.1182/blood-2025-2070

Published: 2025

Journal Articles

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2025-2068

Published: 2025

Journal Articles

Clinical and biological correlates of blast-transformed chronic myelomonocytic leukemia (CMML): A multicenter study of 493 paired cases at chronic phase and at blast transformation

Blood (2025) 146 (Supplement 1): 2081.

https://doi.org/10.1182/blood-2025-2081

Published: 2025

Journal Articles

Occurrence of immune-mediated inflammatory disorders (IMIDs) during the course of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) negatively impacts overall survival (OS): A cohort-based study

Jose Torregrosa, Thomas Brunet, Lin-Pierre Zhao, Pierre Fenaux, Arsene Mekinian, Maria Julia Montoro, David Valcarcel, Sophie Dimicoli-Salazar, Estibaliz Lazarro, Claudio Fozza, Yohann Foucher

Blood (2025) 146 (Supplement 1): 2076.

https://doi.org/10.1182/blood-2025-2076

Published: 2025

Journal Articles

Safe: A multimodal, scalable and clinically-oriented comprehensive framework for synthetic data validation in hematology

Blood (2025) 146 (Supplement 1): 396.

https://doi.org/10.1182/blood-2025-396

Published: 2025

Journal Articles

Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy

Jay Yang, Joseph Jurcic, Christian Recher, Pierre Fenaux, Andrew Wei, Antonio Curti, Justin Watts, Eunice Wang, Brian Jonas, Jorge Cortes, Aaron Sheppard, Sophia Wang, Stephane De Botton

Blood (2025) 146 (Supplement 1): 5213.

https://doi.org/10.1182/blood-2025-5213

Published: 2025

Journal Articles

Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial

Valeria Santini, Matteo Della Porta, Rami Komrokji, Veronika Pozharskaya, Thalia Farazi, Karen Keeperman, Yinzhi Lai, Dimana Miteva, Tracy Krimmel, Barkha Aggarwal, David Valcarcel, Pierre Fenaux, Jake Shortt, Uwe Platzbecker, Guillermo Garcia-Manero, Amer Zeidan

Blood (2025) 146 (Supplement 1): 792.

https://doi.org/10.1182/blood-2025-792

Published: 2025

Journal Articles

Does stringent cytoreduction improve survival in myeloproliferative chronic myelomonocytic leukemia? a correlative study on the dacota trial.

Blood (2025) 146 (Supplement 1): 791.

https://doi.org/10.1182/blood-2025-791

Published: 2025

Journal Articles

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

Blood (2025) 146 (Supplement 1): 235.

https://doi.org/10.1182/blood-2025-235

Published: 2025

Journal Articles

Development and validation of synthetic data generation over a federated learning computing framework to accelerate innovation and boost personalized medicine in hematological diseases

Blood (2025) 146 (Supplement 1): 4350.

https://doi.org/10.1182/blood-2025-4350

Published: 2025

Journal Articles

Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)

Blood (2025) 146 (Supplement 1): 2074.

https://doi.org/10.1182/blood-2025-2074

Published: 2025

Journal Articles

Lupus-like manifestations in MDS/CMML: Evidence for clonal origin and therapeutic implications

Blood (2025) 146 (Supplement 1): 7387.

https://doi.org/10.1182/blood-2025-7387

Published: 2025

Journal Articles

Azacitidine (AZA) and venetoclax (VEN) combination for the treatment of immune mediate inflammatory diseases (IMID) associated with myeloid neoplasms (MN)

Armelle Otiniano, Vincent Jachiet, Jerome Hadjadj, Mael Heiblig, Pierre LOZAC H, Mathieu Wemeau, Maxime Battistella, Mirabelle Ruyer Thompson, Eve Zakine, Urbain Tauveron-Jalenques, Marc Ruivard, Benoit De Renzis, Pierre Fenaux, Olivier Fain, Lin-Pierre Zhao, Arsene Mekinian

Blood (2025) 146 (Supplement 1): 5630.

https://doi.org/10.1182/blood-2025-5630

Published: 2025

Journal Articles

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Blood (2025) 146 (Supplement 1): 490.

https://doi.org/10.1182/blood-2025-490

Published: 2025

Journal Articles

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX

Vincent Jachiet, Olivier Kosmider, Maxime Beydon, Jérôme Hadjadj, Lin-Pierre Zhao, Vincent Grobost, Valentin Lacombe, Guillaume Le Guenno, Yann Nguyen, Jean-Benoît Arlet, Jérémie Dion, Maël Heiblig, Alice Garnier, Maxime Samson, Achille Aouba, Sylvain Thépot, Sophie Dimicoli-Salazar, Fabien Dutasta, Benoît Faucher, Estibaliz Lazaro, Véronique Morel, Antoine Néel, Roderau Outh, Holy Bezanahary, Julien Rossignol, Anne-Sophie Alary, Audrey Bidet, Pauline Blateau, Anne Bouvier, Guilaine Boursier, Matthieu Decamp, Benjamin Lebecque, Yannick Le Bris, Pierre Sujobert, Alice Marceau-Renaut, Cédric Pastoret, David Rizzo, Nathalie Boiret-Dupré, Lara Boucher, Stéphanie Dulucq, Franck Genevieve, Cassandra Jadeau, Pierre Lemaire, Romain Vazquez, Jean-Baptiste Rieu, Olivier Fain, Sophie Georgin-Lavialle, Lucie Rigolot, Lise Larcher, Pierre Hirsch, Benjamin Terrier, Pierre Fenaux, Arsène Mékinian, Thibault Comont

Blood (2025) 146 (12): 1450–1461.

https://doi.org/10.1182/blood.2024028133

Published: 2025

Includes: Supplemental data

Journal Articles

The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy

Blood (2025) 146 (5): 601–611.

https://doi.org/10.1182/blood.2024027506

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting ephrin A3 in the bone marrow niche offers a promising therapeutic strategy to impede hematopoietic stem cell maintenance in MDS patients

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

Characteristics and prognostic significance of myelodysplastic syndrome (MDS)-related features in vexas syndrome

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Clinical and biological correlates of blast-transformed chronic myelomonocytic leukemia (CMML): A multicenter study of 493 paired cases at chronic phase and at blast transformation

Occurrence of immune-mediated inflammatory disorders (IMIDs) during the course of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) negatively impacts overall survival (OS): A cohort-based study

Safe: A multimodal, scalable and clinically-oriented comprehensive framework for synthetic data validation in hematology

Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy

Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial

Does stringent cytoreduction improve survival in myeloproliferative chronic myelomonocytic leukemia? a correlative study on the dacota trial.

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

Development and validation of synthetic data generation over a federated learning computing framework to accelerate innovation and boost personalized medicine in hematological diseases

Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)

Lupus-like manifestations in MDS/CMML: Evidence for clonal origin and therapeutic implications

Azacitidine (AZA) and venetoclax (VEN) combination for the treatment of immune mediate inflammatory diseases (IMID) associated with myeloid neoplasms (MN)

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX

The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only